• Aisen P. S., Saumier D., Briand R., Laurin J., Gervais F., Tremblay P. and Garceau D. (2006) A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67, 17571763.
  • Aisen P. S., Gauthier S., Ferris S. H. et al. (2011) Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch. Med. Sci. 7, 102111.
  • Bard F., Cannon C., Barbour R. et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916919.
  • Blennow K., Zetterberg H., Wei J., Liu E., Black R. and Grundman M. (2010) Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease. Alzheimers. Dement. 6, 2.
  • Blennow K., Zetterberg H., Rinne J. O., Salloway S., Wei J., Black R., Grundman M., Liu E. and for the, A. A. B. I. (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. 69, 10021010.
  • Chavez-Gutierrez L., Bammens L., Benilova I. et al. (2012) The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 22612274.
  • DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M. and Holtzman D. M. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 88508855.
  • DeMattos R. B., Bales K. R., Cummins D. J., Paul S. M. and Holtzman D. M. (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 22642267.
  • Farlow M., Arnold S. E., van Dyck C. H. et al. (2012) Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 8, 261271.
  • Fleisher A. S., Raman R., Siemers E. R. et al. (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 10311038.
  • Golde T. E., Schneider L. S. and Koo E. H. (2011) Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69, 203213.
  • Green R. C., Schneider L. S., Amato D. A., Beelen A. P., Wilcock G., Swabb E. A., Zavitz K. H. and Tarenflurbil Phase 3 Study, G. (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 25572564.
  • Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • Hardy J., Duff K., Hardy K. G., Perez-Tur J. and Hutton M. (1998) Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci. 1, 355358.
  • Jonsson T., Atwal J. K., Steinberg S. et al. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 9699.
  • Karran E., Mercken M. and De Strooper B. (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698712.
  • Klunk W. E., Engler H., Nordberg A. et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55, 306319.
  • Lobello K., Ryan J. M., Liu E., Rippon G. and Black R. (2012) Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. Int. J. Alzheimers Dis. 2012, 628070.
  • Racke M. M., Boone L. I., Hepburn D. L. et al. (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25, 629636.
  • Rinne J. O., Brooks D. J., Rossor M. N. et al. (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363372.
  • Rowe C. C., Ellis K. A., Rimajova M. et al. (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31, 12751283.
  • Salloway S., Sperling R., Gilman S. et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 20612070.
  • Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173177.
  • Wilcock G. K., Black S. E., Hendrix S. B., Zavitz K. H., Swabb E. A., Laughlin M. A. and Tarenflurbil Phase, I. I. S. i. (2008) Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 7, 483493.
  • Wimo A. and Prince M. (2011) World Alzheimer report 2010: the global economic impact of dementia, in Alzheimer's Disease International pp. 152. Alzheimer's Disease International, London.